Search

Author/Creator Aldea, M

2. 364OClinical utility of ctDNA genomic alterations (GA) based on ESMO scale for clinical actionability of molecular targets (ESCAT) in advanced NSCLC. (24th November 2019)

Authors:
Mezquita, L; Planchard, D; Suarez, M Dorta; Aldea, M; Naltet, C; Lamberts, V; Grecea, M; Martin-Romano, P; de Kievit, F; Jovelet, C; Lacroix, L; Masip, J Remon; Lavaud, P; Gazzah, A; Morris, C; Howarth, K; Green, E; Vassal, G; Massard, C; Besse, B
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Evaluating the appropriateness of a community pharmacy model for a colorectal cancer screening program in Catalonia (Spain). (January 2017)

Authors:
Santolaya, M; Aldea, M; Grau, J; Estrada, M; Barau, M; Buron, A; Francesc, M; Castell, A; Rodriguez, C; Gascón, P; Rius, P; Guayta-Escolies, R
Journal:
Journal of oncology pharmacy practice
Issue:
Volume 23:Number 1(2017)
Page Start:
26
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Comparison of haematopoietic stem cell engraftment through the retro-orbital venous sinus and the lateral vein: alternative routes for bone marrow transplantation in mice. (April 2015)

Authors:
Leon-Rico, D; Fernández-García, M; Aldea, M; Sánchez, R; Peces-Barba, M; Martinez-Palacio, J; Yáñez, RM; Almarza, E
Journal:
Laboratory animals
Issue:
Volume 49:Number 2(2015:Apr.)
Page Start:
132
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗